Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (n = 8) demonstrated a high level of correlation with the PDX (n = 2) and clinical response in patients (n = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.

中文翻译：

---

膀胱癌球体的建立并在微流控平台中培养用于预测药物反应

含顺铂的联合化疗已成为晚期膀胱癌患者的标准治疗方法。然而，近 50% 的患者没有反应。为了指导选择更有效的化疗药物，本研究建立了膀胱癌球体微流控药物敏感性分析系统。建立了膀胱癌球体，并在定制的微流体装置中成功培养，以评估其对不同化疗药物的反应。体外药物敏感性结果也与患者来源的异种移植（PDX）模型和患者的临床反应进行了比较。因此，膀胱癌球体忠实地再现了其相应亲代肿瘤的组织病理学和遗传特征。此外，球体的体外药物敏感性结果 ( n = 8) 与 PDX ( n  = 2) 和患者临床反应 ( n  = 2) 具有高度相关性。我们的研究强调了将膀胱癌球体和微流体装置相结合作为个性化选择化疗药物的高效、准确平台的潜力。